<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aeon Biopharma, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/aeon-biopharma-inc</link>
    <description>Latest news and press releases for Aeon Biopharma, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 03 Apr 2026 20:10:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aeon-biopharma-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7301151cc36e47532c9a2.webp</url>
      <title>Aeon Biopharma, Inc.</title>
      <link>https://6ix.com/company/aeon-biopharma-inc</link>
    </image>
    <item>
      <title>AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-section-711</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-inducement-grants-under-nyse-american-llc-company-guide-section-711</guid>
      <pubDate>Fri, 03 Apr 2026 20:10:00 GMT</pubDate>
      <description>IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) approved th</description>
    </item>
    <item>
      <title>AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-receives-additional-notice-related-to-nyse-american-continued-listing-standards</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-receives-additional-notice-related-to-nyse-american-continued-listing-standards</guid>
      <pubDate>Fri, 03 Apr 2026 20:05:00 GMT</pubDate>
      <description>IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that, following its year-end financial results, the Company is not in compliance with an additio</description>
    </item>
    <item>
      <title>AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-full-year-2025-financial-results-and-highlights-positive-comparative-analytical-results-and-fda-feedback-for-abp-450-biosimilar-program</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-full-year-2025-financial-results-and-highlights-positive-comparative-analytical-results-and-fda-feedback-for-abp-450-biosimilar-program</guid>
      <pubDate>Mon, 30 Mar 2026 20:05:00 GMT</pubDate>
      <description>– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chie</description>
    </item>
    <item>
      <title>AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-fda-feedback-following-bpd-type-2a-meeting-for-the-abp-450-biosimilar-program</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-fda-feedback-following-bpd-type-2a-meeting-for-the-abp-450-biosimilar-program</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
      <description>FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps in the development of ABP-450 as a biosimilar to BOTOX® IRVINE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as</description>
    </item>
    <item>
      <title>AEON Biopharma Appoints John Bencich as Chief Financial Officer</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-appoints-john-bencich-as-chief-financial-officer-2</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-appoints-john-bencich-as-chief-financial-officer-2</guid>
      <pubDate>Mon, 09 Mar 2026 20:05:00 GMT</pubDate>
      <description>Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestonesIRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Finan</description>
    </item>
    <item>
      <title>AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-abstract-accepted-for-presentation-at-2026-american-academy-of-neurology-aan-annual-meeting-69</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-abstract-accepted-for-presentation-at-2026-american-academy-of-neurology-aan-annual-meeting-69</guid>
      <pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
      <description>IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously report</description>
    </item>
    <item>
      <title>AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-bpd-type-2a-meeting-with-fda-and-shareholder-approval-of-the-november-transactions</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-bpd-type-2a-meeting-with-fda-and-shareholder-approval-of-the-november-transactions</guid>
      <pubDate>Wed, 21 Jan 2026 21:05:00 GMT</pubDate>
      <description>- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a</description>
    </item>
    <item>
      <title>AEON Biopharma Announces Execution of Exchange Agreement with Daewoong</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-execution-of-exchange-agreement-with-daewoong</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-execution-of-exchange-agreement-with-daewoong</guid>
      <pubDate>Mon, 15 Dec 2025 21:05:00 GMT</pubDate>
      <description>- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock – - Exchange remains subject to shareholder approval - IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market ent</description>
    </item>
    <item>
      <title>AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-first-closing-of-pipe-investment-and-provides-update-on-fda-type-2a-meeting-scheduling</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-first-closing-of-pipe-investment-and-provides-update-on-fda-type-2a-meeting-scheduling</guid>
      <pubDate>Thu, 20 Nov 2025 13:30:00 GMT</pubDate>
      <description>- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced the first closing of its previously announced private placement (“PIPE”). A</description>
    </item>
    <item>
      <title>AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-third-quarter-2025-results-including-positive-abp-450-biosimilarity-data-and-strategic-positioning-for-continued-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-third-quarter-2025-results-including-positive-abp-450-biosimilarity-data-and-strategic-positioning-for-continued-growth</guid>
      <pubDate>Fri, 14 Nov 2025 13:30:00 GMT</pubDate>
      <description>– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON’s balance sheet, reduce ou</description>
    </item>
    <item>
      <title>AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-positive-and-robust-biosimilarity-results-identical-amino-acid-sequence-and-highly-similar-functional-analysis-data</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-positive-and-robust-biosimilarity-results-identical-amino-acid-sequence-and-highly-similar-functional-analysis-data</guid>
      <pubDate>Thu, 13 Nov 2025 13:30:00 GMT</pubDate>
      <description>- 100% match of visible amino acid sequence confirmed between ABP-450 and BOTOX® - - Functional assays demonstrate strong similarity in potency and composition, with directionally consistent enzymatic activity results - IRVINE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) b</description>
    </item>
    <item>
      <title>AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-fda-bpd-type-2a-meeting-for-abp-450-on-november-19</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-announces-fda-bpd-type-2a-meeting-for-abp-450-on-november-19</guid>
      <pubDate>Wed, 01 Oct 2025 12:00:00 GMT</pubDate>
      <description>- Meeting date aligns with prior guidance - - FDA to review AEON’s analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Biosimilar Biological Product Development (BPD) Type 2a meeting for ABP-450 on No</description>
    </item>
    <item>
      <title>AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
      <description>– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing</description>
    </item>
    <item>
      <title>AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-to-present-at-the-aegis-capital-corp-virtual-conference-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-to-present-at-the-aegis-capital-corp-virtual-conference-2025</guid>
      <pubDate>Mon, 19 May 2025 20:05:00 GMT</pubDate>
      <description>IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. Please register here to</description>
    </item>
    <item>
      <title>AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/aeon-biopharma-inc/news/aeon-biopharma-reports-first-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
      <description>– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company’s President and Chief Executive Officer; Mr. Bancroft also joined AEON’s Board of Di</description>
    </item>
  </channel>
</rss>